TheraRadar
Clinical-Stage Companies / OPKO Health

OPKO Health

Pre-Approval PRO BETA
35
Total Trials
7
Phase 3
18
Phase 2
0
Recruiting
292
Score

Pipeline by Phase

Phase 3
7
Phase 2
18
Phase 1
11

Therapeutic Focus

Secondary Hyperparathyroidism Vitamin D Insufficiency Alzheimer's Disease Secondary Hyperparathyroidism Due to Renal Causes Vitamin D Deficiency

Clinical Trials (35)

NCT05543928 Phase 3 TERMINATED

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

Started: 1/31/2023

NCT02968004 Phase 3 COMPLETED

Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Started: 12/1/2016

NCT01909479 Phase 3 TERMINATED

A Phase 3, Multicenter Study To Evaluate The Efficacy And Safety Of MOD-4023 In Adults With Growth Hormone Deficiency

Started: 6/1/2013

NCT03874013 Phase 3 COMPLETED

Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency

Started: 12/7/2017

NCT02282813 Phase 3 COMPLETED

Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002

Started: 4/1/2013

NCT00557791 Phase 3 WITHDRAWN

Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)

Started: 11/1/2009

NCT03602261 Phase 2 TERMINATED

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Started: 7/9/2018

NCT07494045 Phase 2 NOT YET RECRUITING

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

Started: 6/1/2026

NCT02500316 Phase 2 COMPLETED

Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Started: 2/1/2014

NCT04551911 Phase 2 COMPLETED

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Started: 11/2/2020

NCT03297398 Phase 2 TERMINATED

Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

Started: 2/21/2018

NCT03406377 Phase 2 COMPLETED

Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects

Started: 4/2/2018

NCT02119819 Phase 2 COMPLETED

A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes

Started: 4/1/2014

NCT01592500 Phase 2 COMPLETED

Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Started: 2/1/2012

NCT01791725 Phase 2 COMPLETED

A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia

Started: 9/1/2013

NCT01766336 Phase 2 TERMINATED

A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Started: 1/1/2013

NCT00934050 Phase 2 COMPLETED

ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease

Started: 6/1/2009

NCT01674010 Phase 2 TERMINATED

Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder

Started: 8/1/2012

NCT01735630 Phase 2 COMPLETED

Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease

Started: 11/1/2012

NCT01225666 Phase 2 COMPLETED

MOD-4023 (Long-Lasting Human Growth Hormone (hGH)) Study in Growth Hormone Deficient Adults (GHDA)

Started: 8/1/2010

NCT01219855 Phase 2 COMPLETED

Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT)

Started: 10/1/2010

NCT01453634 Phase 2 WITHDRAWN

Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018)

Started: 1/1/2013

NCT00743002 Phase 2 COMPLETED

A Trial of TT223 in Patients With Type 2 Diabetes Who Are Taking Metformin and/or Thiazolidinedione

Started: 8/1/2008

NCT07512427 Phase 1 NOT YET RECRUITING

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

Started: 12/1/2026

NCT02188303 Phase 1 TERMINATED

A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants

Started: 7/1/2014

NCT02418793 Phase 1 COMPLETED

A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B

Started: 5/1/2015

NCT03810664 Phase 1 COMPLETED

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Started: 1/18/2019

NCT02919800 Phase 1 COMPLETED

A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

Started: 1/22/2017

NCT02418767 Phase 1 COMPLETED

Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers

Started: 1/1/2015

NCT02692781 Phase 1 COMPLETED

A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects

Started: 2/1/2016

NCT01060722 Phase 1 COMPLETED

MOD-4023 Study in Healthy Male Volunteers

Started: 10/1/2009

NCT03660800 Phase 1 COMPLETED

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

Started: 8/20/2018

NCT02274623 Phase 1 COMPLETED

Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid

Started: 12/1/2014

NCT01357421 Phase 1 COMPLETED

Effects of TT301 on Cytokine Levels Post Endotoxin Challenge

Started: 5/1/2011

NCT03588884 Phase 4 COMPLETED

Repeated-dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of CTAP101, Immediate-release Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Chronic Kidney Disease 3-4 and Vitamin D Insufficiency

Started: 6/8/2018

Drug Candidates

OPK-88006 Placebo Calcifediol Oral Capsule Placebo oral capsule CTAP101 MOD-4023 Somatropin Rayaldee Calcifediol Oral Product Cholecalciferol
Activity Status: Active
Last Trial Started: 12/1/2026
Last Trial Ended: 6/19/2024
Trials (12 months): 2
Completed Trials: 24
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.